| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Amebae
Metronidazole acetic acid does not have a specific biological target as it is an inactive metabolite of metronidazole. The parent compound, metronidazole, targets anaerobic bacteria and protozoa by causing DNA damage through the generation of reactive intermediates. Metronidazole acetic acid is formed as a metabolic breakdown product and does not contribute to the antimicrobial activity of the parent drug. |
|---|---|
| ln Vitro |
Metronidazole acetic acid demonstrates mutagenic activity in bacteria. However, it does not exhibit antimicrobial activity as it is an inactive metabolite of metronidazole. The compound's utility is primarily as an analytical standard for the identification and quantification of metronidazole impurities in pharmaceutical preparations.
|
| ln Vivo |
Metronidazole acetic acid is not used as a therapeutic agent and does not exhibit in vivo activity. It is formed as a metabolite following administration of metronidazole. The compound is used as a reference standard in analytical chemistry rather than as a pharmacologically active compound.
|
| Enzyme Assay |
In vitro mutagenicity assays for metronidazole acetic acid involve testing the compound in bacterial mutagenicity tests such as the Ames test, where its ability to induce mutations in bacterial strains is assessed. The compound's identity and purity are confirmed using analytical techniques such as HPLC and mass spectrometry.
|
| Cell Assay |
In vitro cellular assays are not applicable to metronidazole acetic acid, as it is an analytical standard and inactive metabolite rather than a bioactive compound tested directly on cells.
|
| Animal Protocol |
In vivo animal experiments are not applicable to metronidazole acetic acid, as it is an analytical standard and inactive metabolite rather than a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for metronidazole acetic acid are related to its formation as a metabolite of metronidazole. It is an inactive metabolite that is excreted from the body following the administration of the parent drug.
|
| Toxicity/Toxicokinetics |
Metronidazole acetic acid is a potential human carcinogen as it is related to metronidazole. The compound is intended for research use only and should be handled with appropriate safety precautions. Standard laboratory safety protocols should be followed when handling this compound.
|
| References |
[1]. M Chacko, et al. Studies on the Possible Mutagenic Action of Metronidazole. Indian J Exp Biol. 1987 Apr;25(4):240-3.
[2]. M D Mudry, et al. Mutagenic Bioassay of Certain Pharmacological Drugs: III. Metronidazole (MTZ). Mutat Res. 1994 Mar 1;305(2):127-32. [3]. In Schaechter, M.; Engleberg, N. C.; DiRita, V. J. et al. Schaechter's Mechanisms of Microbial Disease. Hagerstown, MD: Lippincott Williams & Wilkins. p. 28. |
| Additional Infomation |
1-Carboxymethyl metronidazole is an organic nitrogen and organic oxygen compound whose function is related to α-amino acids.
Metronidazole acetic acid (Metronidazole Impurity G) (CAS#: 1010-93-1) has the molecular formula C6H7N3O4 and a molecular weight of 185.14. It is a metabolite of metronidazole and has mutagenic activity in bacteria. It is a potential impurity found in commercial preparations of metronidazole. The compound is intended for research use only. |
| Molecular Formula |
C6H7N3O4
|
|---|---|
| Molecular Weight |
185.14
|
| Exact Mass |
185.044
|
| CAS # |
1010-93-1
|
| PubChem CID |
115249
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6g/cm3
|
| Boiling Point |
475.9ºC at 760mmHg
|
| Flash Point |
241.6ºC
|
| Vapour Pressure |
7.28E-10mmHg at 25°C
|
| Index of Refraction |
1.646
|
| LogP |
0.707
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
226
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NC=C([N+]([O-])=O)N1CC(O)=O
|
| InChi Key |
RVEGZXNRNWUYKI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H7N3O4/c1-4-7-2-5(9(12)13)8(4)3-6(10)11/h2H,3H2,1H3,(H,10,11)
|
| Chemical Name |
2-(2-methyl-5-nitroimidazol-1-yl)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (1350.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (11.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (11.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (11.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4013 mL | 27.0066 mL | 54.0132 mL | |
| 5 mM | 1.0803 mL | 5.4013 mL | 10.8026 mL | |
| 10 mM | 0.5401 mL | 2.7007 mL | 5.4013 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
